INNATE PHARMA (EPA:IPH) Innate Pharma (Euronext Paris: FR0010331421 – IPH) announces that the French version of the 2009 Reference Document, including the Annual Financial Report, as well as the 2009 Annual Report of the Company, is available on its website

Transparency directive : regulatory news

29/04/2010 17:38

PRESS RELEASE

INNATE PHARMA ANNOUNCES THE RELEASE OF ITS ANNUAL REPORT AND REFERENCE DOCUMENT
                                  (IN FRENCH)

Marseilles, France, April 29, 2010

Innate Pharma (Euronext Paris: FR0010331421 - IPH) announces that the French
version of the 2009 Reference Document, including the Annual Financial Report,
as well as the 2009 Annual Report of the Company, is available on its website
(www.innate-pharma.com).

The Reference Document of the Company (in French) is also available on the
website of the AMF, the French stock-market authorities (www.amf-france.org).

The English version of the 2009 Reference Document will be made available on
Innate Pharma's website at the end of May 2010.

Hard copies of these documents are available upon request to the investor
relations department of the Company.

About Innate Pharma:

Innate Pharma S.A. is a clinical-stage biopharmaceutical company developing
first-in-class immunotherapy drugs for cancer and other severe diseases. The
Company was incorporated in 1999 and listed on NYSE-Euronext in Paris in 2006.
The Company has two drug candidates currently in Phase II clinical trials. Two
of its preclinical programs are out-licensed to Novo Nordisk A/S.

Innate Pharma is based in Marseilles, France, and had 80 employees as at
December 31, 2009.

Learn more about Innate-Pharma at www.innate-pharma.com.

Practical Information about Innate Pharma shares:

ISIN code     FR0010331421
Ticker code   IPH

Disclaimer:

This press release contains certain forward-looking statements. Although the
company believes its expectations are based on reasonable assumptions, these
forward-looking statements are subject to numerous risks and uncertainties,
which could cause actual results to differ materially from those anticipated.
For a discussion of risks and uncertainties which could cause the company's
actual results, financial condition, performance or achievements to differ from
those contained in the forward-looking statements, please refer to the Risk
Factors ("Facteurs de Risque") section of the Document de Reference prospectus
filed with the AMF, which is available on the AMF website
(http://www.amf-france.org) or on Innate Pharma's website.
This press release and the information contained herein do not constitute an
offer to sell or a solicitation of an offer to buy or subscribe to shares in
Innate Pharma in any country.

For additional information, please contact:

Innate Pharma                         Alize Public Relations
Laure-Hélène Mercier                  Caroline Carmagnol
Director, Investor Relations          Phone : +33 (0)1 42 68 86 40
Phone: +33 (0)4 30 30 30 87           Mobile: +33 (0)6 64 18 99 59
investors@innate-pharma.com           caroline@alizerp.com

IPH_AGM 2010

INNATE PHARMA's latest news

05/04/2024 09:34

INNATE PHARMA (EPA:IPH) Innate Pharma (Euronext Paris: FR0010331421 – IPH) announces that the French version of the 2009 Reference Document, including the Annual Financial Report, as well as the 2009 Annual Report of the Company, is available on its website

Transparency directive : regulatory news

INNATE PHARMA's latest news

Other stories